RGNX

Regenxbio Inc. (RGNX) | Rumor.io

Regenxbio

RGNX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,461

Bullish sentiment (50-day avg)56%

Price to earnings ratio-1.99

Market capitalization493.1M

Earnings per share-3.78

Dividend yield (TTM)—

Revenue (annual)170.4M

Net income (annual)-193.9M

Social

What share of all stock conversation is about RGNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 25

Regenxbio presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy, with 60% of participants achieving a greater than two-step improvement on the Diabetic Retinopathy Severity Scale at Year 3.
The data showed no vision-threatening events and zero additional diabetic retinopathy treatments among those participants, providing additional clinical support for the dose selected for the company's registrational program.
Stifel reiterated a Buy rating and $42.00 price target on Regenxbio Inc. following new clinical trial data for the company's gene therapy candidate.

Generated by AI

Sentiment

Of the messages about RGNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +12.5	83.33% +35.68	65.51% -15.7
Bearish	—	0% -12.5	16.67% -35.68	34.49% +15.7

Bullish· Jun 22

The FDA has reversed its rejection of Regenxbio's rare-disease drug, citing existing clinical data as sufficient for approval.
Regenxbio's stock is running hot, up 11.5% on the session, driven by the Duchenne data update, which may be a catalyst for further upside.
The company's stock has significant upside potential, with a potential move to double digits if it can push through the $9 psychological level.

Bearish· Aug 24

The FDA's clinical hold on RGX-121 may be a buying opportunity, as the safety signals are specific to the therapy and not the company's other assets.
The market's overreaction to the clinical hold may be unjustified, as the five spinal abnormalities are asymptomatic and considered likely benign by radiologists.
The company's management communication and trustworthiness are being questioned, with some investors demanding updated safety and functional data for the 202 asset.

Generated by AI

Topics

Of the messages about RGNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	70%	73.17%	74.33%
Analysts	—	15%	19.51%	4.72%
Technical Analysis	—	0%	0%	8.43%
Controversies	—	15%	7.32%	10.21%
Earnings	—	0%	0%	0.65%
Macro	—	0%	0%	1.65%

Earnings· Mar 5

REGENXBIO Inc. ($RGNX) is set to release earnings on 3/6 after the close.
Analysts expect a loss of $0.79 per share (EPS) from the company.
Since the last earnings report, $RGNX stock has gained 11%.

Announcements· Aug 24

REGENXBIO Inc. announced a clinical hold on its investigational gene therapy RGX-121 for Mucopolysaccharidosis type II (MPS II) after asymptomatic spine MRI findings were identified in five participants in the CAMPSIITE study.
The U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-121, delaying plans to resubmit the Biologics License Application (BLA) in the near term.
REGENXBIO does not expect to resubmit the RGX-121 BLA in the near term, and the company remains focused on its other candidates, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter.

Technical Analysis· Mar 9

* The FDA's recent changes in leadership may have a positive impact on the biotech industry, specifically on $RGNX and $QURE.
* $RGNX is showing a solid bounce off recent lows, indicating buyers are stepping in with conviction, which can signal a trend change.
* Traders should watch for support levels on $RGNX and also monitor the performance of the $DJI.

Generated by AI

Community

Of the messages about RGNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	63.64%	91.53%	74.56%	53.98%
Newcomers	36.36%	8.47%	25.44%	46.02%

Regulars· Aug 24

The FDA has placed a clinical hold on RGX-121, a treatment for Hunter Syndrome, due to asymptomatic spine MRI findings in five trial participants, which may lead to a delay in resubmitting the Biologics License Application.
The market's overreaction to the clinical hold may be an opportunity for investors, with the potential for the hold to be lifted within 2-3 months, depending on the findings, and the therapy being considered likely benign.
The company's Duchenne drug, using AAV8 and delivered IV, is a cleaner and more promising asset, with over 5 years of safety data and additional funding from AbbVie, making it a more attractive option for investors.

Newcomers· Aug 24

The newcomers are focused on the potential for a bounce in the stock price, with some expecting a 5-7% increase.
There is concern about the company's recent clinical hold by the FDA, with some users seeking more information about the hold and its potential impact on the company's program.
Some users are questioning the company's decision to focus on its pipeline beyond the Hunter syndrome drug, citing potential inefficiencies and the need for a more streamlined approach.

Generated by AI

In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...

3d agoYahoo Finance

Also Discussed

Investors talking about RGNX also mention

#	Name	Attention
1	uniQure N.V.QURE	0.02%+0.01
2	4D Molecular Therapeutics, Inc.FDMT	0%new
3	Solid Biosciences Inc.SLDB	0.3%new
4	ADVM - Adverum Biotechnologies, Inc.	——
5	Denali Therapeutics Inc.DNLI	0%new
6	MeiraGTx Holdings plcMGTX	0%new
7	Sarepta Therapeutics, Inc.SRPT	0%-0.01
8	Replimune Group, Inc.REPL	0%0
9	Voyager Therapeutics, Inc.VYGR	0%0
10	BioMarin Pharmaceutical IncBMRN	0%+0

Regenxbio Inc.

Healthcare
Biotechnology

REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy. REGENXBIO Inc. develops and commercializes recombinant adeno-associated virus (AAV)–based treatments designed to deliver functional genes to cells and address genetic defects. Its current work centers on therapeutic programs in retinal, metabolic, and neurodegenerative diseases, supported by its proprietary NAV Technology Platform. The company also licenses its AAV gene-delivery technology to other biotechnology partners, combining internal drug development with platform licensing. REGENXBIO Inc. plays a specialized role in the biotechnology market by advancing gene therapy candidates and enabling broader use of AAV-based delivery systems across the life sciences industry.

Website

Location

9804 Medical Center Drive

Rockville, MD, 20850

United States

Social

What share of all stock conversation is about RGNX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 25

Regenxbio presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy, with 60% of participants achieving a greater than two-step improvement on the Diabetic Retinopathy Severity Scale at Year 3.
The data showed no vision-threatening events and zero additional diabetic retinopathy treatments among those participants, providing additional clinical support for the dose selected for the company's registrational program.
Stifel reiterated a Buy rating and $42.00 price target on Regenxbio Inc. following new clinical trial data for the company's gene therapy candidate.

Generated by AI

Sentiment

Of the messages about RGNX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +12.5	83.33% +35.68	65.51% -15.7
Bearish	—	0% -12.5	16.67% -35.68	34.49% +15.7

Bullish· Jun 22

The FDA has reversed its rejection of Regenxbio's rare-disease drug, citing existing clinical data as sufficient for approval.
Regenxbio's stock is running hot, up 11.5% on the session, driven by the Duchenne data update, which may be a catalyst for further upside.
The company's stock has significant upside potential, with a potential move to double digits if it can push through the $9 psychological level.

Bearish· Aug 24

The FDA's clinical hold on RGX-121 may be a buying opportunity, as the safety signals are specific to the therapy and not the company's other assets.
The market's overreaction to the clinical hold may be unjustified, as the five spinal abnormalities are asymptomatic and considered likely benign by radiologists.
The company's management communication and trustworthiness are being questioned, with some investors demanding updated safety and functional data for the 202 asset.

Generated by AI

Topics

Of the messages about RGNX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	70%	73.17%	74.33%
Analysts	—	15%	19.51%	4.72%
Technical Analysis	—	0%	0%	8.43%
Controversies	—	15%	7.32%	10.21%
Earnings	—	0%	0%	0.65%
Macro	—	0%	0%	1.65%

Earnings· Mar 5

REGENXBIO Inc. ($RGNX) is set to release earnings on 3/6 after the close.
Analysts expect a loss of $0.79 per share (EPS) from the company.
Since the last earnings report, $RGNX stock has gained 11%.

Announcements· Aug 24

REGENXBIO Inc. announced a clinical hold on its investigational gene therapy RGX-121 for Mucopolysaccharidosis type II (MPS II) after asymptomatic spine MRI findings were identified in five participants in the CAMPSIITE study.
The U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-121, delaying plans to resubmit the Biologics License Application (BLA) in the near term.
REGENXBIO does not expect to resubmit the RGX-121 BLA in the near term, and the company remains focused on its other candidates, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter.

Technical Analysis· Mar 9

* The FDA's recent changes in leadership may have a positive impact on the biotech industry, specifically on $RGNX and $QURE.
* $RGNX is showing a solid bounce off recent lows, indicating buyers are stepping in with conviction, which can signal a trend change.
* Traders should watch for support levels on $RGNX and also monitor the performance of the $DJI.

Generated by AI

Community

Of the messages about RGNX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	63.64%	91.53%	74.56%	53.98%
Newcomers	36.36%	8.47%	25.44%	46.02%

Regulars· Aug 24

The FDA has placed a clinical hold on RGX-121, a treatment for Hunter Syndrome, due to asymptomatic spine MRI findings in five trial participants, which may lead to a delay in resubmitting the Biologics License Application.
The market's overreaction to the clinical hold may be an opportunity for investors, with the potential for the hold to be lifted within 2-3 months, depending on the findings, and the therapy being considered likely benign.
The company's Duchenne drug, using AAV8 and delivered IV, is a cleaner and more promising asset, with over 5 years of safety data and additional funding from AbbVie, making it a more attractive option for investors.

Newcomers· Aug 24

The newcomers are focused on the potential for a bounce in the stock price, with some expecting a 5-7% increase.
There is concern about the company's recent clinical hold by the FDA, with some users seeking more information about the hold and its potential impact on the company's program.
Some users are questioning the company's decision to focus on its pipeline beyond the Hunter syndrome drug, citing potential inefficiencies and the need for a more streamlined approach.

Generated by AI

Regenxbio

Social

Sep 25

Bullish· Jun 22

Bearish· Aug 24

Earnings· Mar 5

Announcements· Aug 24

Technical Analysis· Mar 9

Regulars· Aug 24

Newcomers· Aug 24

H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data

Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn

Stifel reiterates Regenxbio stock rating on gene therapy data

Why is Regenxbio stock climbing today?

Regenxbio stock gains on positive gene therapy trial data

REGENXBIO at Morgan Stanley conference: late-stage gene therapy push

Also Discussed

Regenxbio Inc.

Company Information

Location

H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data

Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn

Stifel reiterates Regenxbio stock rating on gene therapy data

Why is Regenxbio stock climbing today?

Regenxbio stock gains on positive gene therapy trial data

REGENXBIO at Morgan Stanley conference: late-stage gene therapy push

Also Discussed

Social

Sep 25

Bullish· Jun 22

Bearish· Aug 24

Earnings· Mar 5

Announcements· Aug 24

Technical Analysis· Mar 9

Regulars· Aug 24

Newcomers· Aug 24